We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(Reuters) Aug 4, 2020 - Bayer said it is finding it hard to identify cases of the rare tumour types that qualify for treatment with Vitrakvi, a precision cancer drug which it hopes will improve prospects of its drugs division.
(Yahoo! Finance) Aug 4, 2020 - T-Cure Bioscience, Inc. today announced that the Company has extended its ongoing research collaboration with the National Heart Lung and Blood Institute (NHLBI), through a formal Collaborative Research and Development Agreement (CRADA) to advance the Company’s HERV-E targeting TCR therapy for renal cell cancer.
(Novartis) Aug 4, 2020 - Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate. Kymriah previously received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in r/r FL based on preliminary ELARA trial findings, reflecting the unmet need for additional treatment options for this cancer type.
(Yahoo! Finance) Aug 4, 2020 - BryoLogyx, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia (ALL) and lymphoma.
(Pharmaphorum [UK]) Aug 3, 2020 - At around $198,000 for the first year Monjuvi’s wholesale cost is pricey but may work out as less expensive than CAR-Ts from Novartis and Gilead, depending on how long patients stay on treatment. Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumbersome CAR-T therapy.
(MSK) Aug 3, 2020 - Having two mutated copies of the TP53 gene — as opposed to a single mutated copy — is associated with worse outcomes in a blood cancer called myelodysplastic syndrome, according to a new study led by researchers at Memorial Sloan Kettering. Considered the “guardian of the genome,” TP53 is the most commonly mutated gene in cancer. TP53’s normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells.
(Personalis) Aug 3, 2020 - Personalis, Inc. today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients.
(OneOncology) Aug 4, 2020 - OneOncology, a national partnership of independent oncology practices, today announced that Los Angeles Cancer Network (LACN) is joining the platform as the oncology network expands into California. LACN has 18 providers who care for patients at nine locations throughout the greater Los Angeles area. The independently owned practice treats more than 2,500 patients annually along the continuum of cancer care from screening and diagnosis to cutting-edge therapies and clinical trials to survivorship or end-of-life care.
(Penn Medicine) Aug 4, 2020 - Funding from National Cancer Institute is part of the Beau Biden Cancer Moonshot Initiative.
(Celsion) Aug 4, 2020 - Celsion Corporation today provided an update on its ongoing review of unblinded data from the second pre-planned interim analysis of the global Phase III OPTIMA Study of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer. The Company announces it will continue following patients for overall survival (OS), noting that the unexpected and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim analysis on July 9, 2020, may be associated with a data maturity issue.